SCHEMBL5455855

SCHEMBL5455855

CCOCCOC1OCCc2c1sc(NC(=O)C1CC1)c2C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.45
ALDH1A1 P00352 8/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
MAPK10 P53779 1/20 0.41
HPGD P15428 4/20 0.39
KMT2A Q03164 2/20 0.39
MDM2 Q00987 1/20 0.39
MAPT P10636 6/20 0.39
KDM4E B2RXH2 4/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
REV1 Q9UBZ9 2/20 0.39
MAPK1 P28482 2/20 0.39
CNR2 P34972 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 2/20 0.38
GAA P10253 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459693 0.91 FLT3 (0.49) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5453699 0.90 FLT3 (0.47) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5453327 0.87 FLT3 (0.47) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5449695 0.87 FLT3 (0.43) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5451643 0.76 FLT3 (0.55) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5458311 0.75 FLT3 (0.52) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5455200 0.72 FLT3 (0.46) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5455639 0.72 KMT2A (0.58) ALDH1A1HSD17B10TSHRHPGDKMT2A
SCHEMBL5449035 0.71 FLT3 (0.47) FLT3ALDH1A1HSD17B10TSHRMAPK10
SCHEMBL5457860 0.70 FLT3 (0.44) FLT3ALDH1A1HSD17B10TSHRMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885ALDH1A1 1153/4885HSD17B10 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.